DoD (Army contracting): ~$12.5B for 10M courses of an oral antiviral (PF-07321332) — a contract with Pfizer (USAspending)

1Procuring 10 million courses of an oral antiviral

This contract covers 10 million treatment courses of the oral protease inhibitor "PF-07321332." PF-07321332 is the development code name for nirmatrelvir, the active component of the COVID-19 oral treatment "Paxlovid" (Paxlovid combines nirmatrelvir with ritonavir).

2What it means that the drug is oral

Unlike a medicine given by infusion or injection, an oral drug can be taken at home without a trip to a health-care facility. For a treatment meant to be started early after symptoms begin, that ease of delivery translates directly into ease of use. The fact that the quantity is counted in treatment courses — one full run of doses for one person — rather than in vials or doses reflects a procurement built around that use.

3Why the defense contracting machinery was used

4Being oral changes the shape of the procurement

Unlike a drug given by infusion or injection, an oral medicine can be taken at home without visiting a clinic. That difference shows up not only in reach but in how the quantity is counted.

For a therapeutic meant to be used early after onset, that ease of delivery tells. A scale of 10 million treatment courses shows a government making an enormous, effectively prepaid purchase from a single company under emergency conditions. PF-07321332 is the development code for nirmatrelvir, the active component of the oral COVID-19 therapeutic Paxlovid.